Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome

Trial Profile

Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONEE
  • Sponsors OrbusNeich
  • Most Recent Events

    • 30 Oct 2017 Results presented in an OrbusNeich media release.
    • 30 Oct 2017 According to an OrbusNeich media release, new results were reported in the First Report Investigations session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
    • 30 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top